Skip to main content
SpringerLink
Log in

The Future: Combination Systemic Therapy for Hepatocellular Carcinoma

  • Chapter
  • First Online:
Hepatocellular Carcinoma:

  • 1204 Accesses

Abstract

Hepatocellular carcinoma (HCC) is a potentially curable tumor by surgical resection, local ablation, or liver transplantation. However, the majority of patients with HCC present with advanced stage disease, which is most commonly, accompanied by severe background liver disease. Hence, curative treatments are feasible for only a small fraction of patients with localized disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Lang L (2008) FDA approves sorafenib for patients with inoperable liver cancer. Gastroenterology 134:379

    Google Scholar 

  2. Simonetti RG, Liberati A, Angiolini C et al (1997) Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 8:117–136

    Article  CAS  PubMed  Google Scholar 

  3. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

    Article  CAS  PubMed  Google Scholar 

  4. Yao DF, Dong ZZ, Yao M (2007) Specific molecular markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 6:241–247

    CAS  PubMed  Google Scholar 

  5. Marongiu F, Doratiotto S, Montisci S et al (2008) Liver repopulation and carcinogenesis: two sides of the same coin? Am J Pathol 172:857–864

    Article  PubMed  Google Scholar 

  6. Varnholt H (2008) The role of microRNAs in primary liver cancer. Ann Hepatol 7:104–113

    CAS  PubMed  Google Scholar 

  7. McGivern DR, Lemon SM (2009) Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol 4:399–415

    Article  CAS  PubMed  Google Scholar 

  8. Pang RW, Poon RT (2007) From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. Oncology 72(Suppl 1):30–44

    Article  CAS  PubMed  Google Scholar 

  9. Jain RK (2005) Antiangiogenic therapy for cancer: current and emerging concepts. Oncology (Williston Park) 19:7–16

    Google Scholar 

  10. Tovar V, Villanueva A, Llovet JM (2007) [Cell biology and genetics in liver cancer]. Gastroenterol Hepatol 30:360–369

    Article  PubMed  Google Scholar 

  11. Calvisi DF, Pinna F, Ladu S et al (2008) Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis 29:1639–1647

    Article  CAS  PubMed  Google Scholar 

  12. Tam KH, Yang ZF, Lau CK et al (2009) Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett 273:201–209

    Article  CAS  PubMed  Google Scholar 

  13. Ladu S, Calvisi DF, Conner EA et al (2008) E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer. Gastroenterology 135:1322–1332

    Article  CAS  PubMed  Google Scholar 

  14. Lang SA, Moser C, Fichnter-Feigl S et al (2009) Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice. Hepatology 49: 523–532

    Article  CAS  PubMed  Google Scholar 

  15. Huynh H, Ngo VC, Koong HN et al (2009) Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. J Cell Mol Med

    Google Scholar 

  16. Treiber G (2009) mTOR inhibitors for hepatocellular cancer: a forward-moving target. Expert Rev Anticancer Ther 9: 247–261

    Article  CAS  PubMed  Google Scholar 

  17. Tanaka S, Arii S (2009) Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci 100:1–8

    Article  CAS  PubMed  Google Scholar 

  18. Rizell M, Andersson M, Cahlin C et al (2008) Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer. Int J Clin Oncol 13:66–70

    Article  CAS  PubMed  Google Scholar 

  19. Monaco AP (2009) The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 87:157–163

    Article  CAS  PubMed  Google Scholar 

  20. Thomas MB, Chadha R, Glover K et al (2007) Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 110:1059–1067

    Article  CAS  PubMed  Google Scholar 

  21. Philip PA, Mahoney MR, Allmer C et al (2005) Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J Clin Oncol 23:6657–6663

    Article  CAS  PubMed  Google Scholar 

  22. Finn RS, Zhu AX (2009) Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 9: 503–509

    Article  CAS  PubMed  Google Scholar 

  23. Siegel AB, Cohen EI, Ocean A et al (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992–2998

    Article  CAS  PubMed  Google Scholar 

  24. Bukowski RM (2008) What role do combinations of interferon and targeted agents play in the first-line therapy of metastatic renal cell carcinoma? Clin Genitourin Cancer 6:S14–S21

    Article  CAS  PubMed  Google Scholar 

  25. Chowdhury S, Larkin JM, Gore ME (2008) Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies. Eur J Cancer 44:2152–2161

    Article  CAS  PubMed  Google Scholar 

  26. Kruck S, Kuczyk MA, Gakis G et al (2008) Novel therapeutic options in metastatic renal cancer – review and post ASCO 2007 update. Rev Recent Clin Trials 3:212–216

    Article  CAS  PubMed  Google Scholar 

  27. Papaetis GS, Karapanagiotou LM, Pandha H et al (2008) Targeted therapy for advanced renal cell cancer: cytokines and beyond. Curr Pharm Des 14:2229–2251

    Article  CAS  PubMed  Google Scholar 

  28. Rini BI, Flaherty K (2008) Clinical effect and future considerations for molecularly-targeted therapy in renal cell carcinoma. Urol Oncol 26:543–549

    CAS  PubMed  Google Scholar 

  29. Wysocki PJ, Zolnierek J, Szczylik C et al (2008) Targeted therapy of renal cell cancer. Curr Opin Investig Drugs 9:570–575

    CAS  PubMed  Google Scholar 

  30. Wong SF (2005) Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 27:684–694

    Article  CAS  PubMed  Google Scholar 

  31. Folprecht G, Lutz MP, Schoffski P et al (2006) Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Ann Oncol 17:450–456

    Article  CAS  PubMed  Google Scholar 

  32. Rougier P, Lepere C (2005) Second-line treatment of patients with metastatic colorectal cancer. Semin Oncol 32:S48–S54

    Article  CAS  PubMed  Google Scholar 

  33. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342

    Article  CAS  PubMed  Google Scholar 

  34. Fernando NH, Hurwitz HI (2004) Targeted therapy of colorectal cancer: clinical experience with bevacizumab. Oncologist 9(Suppl 1):11–18

    Article  CAS  PubMed  Google Scholar 

  35. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502–3508

    Article  CAS  PubMed  Google Scholar 

  36. Simkens L, Tol J, Koopman M et al (2008) Current questions in the treatment of advanced colorectal cancer: the CAIRO studies of the Dutch Colorectal Cancer Group. Clin Colorectal Cancer 7:105–109

    Article  CAS  PubMed  Google Scholar 

  37. Azad NS, Posadas EM, Kwitkowski VE et al (2008) Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 26:3709–3714

    Article  CAS  PubMed  Google Scholar 

  38. Hirata A, Ogawa S, Kometani T et al (2002) ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Res 62:2554–2560

    CAS  PubMed  Google Scholar 

  39. Viloria-Petit A, Crombet T, Jothy S et al (2001) Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61:5090–5101

    CAS  PubMed  Google Scholar 

  40. Ciardiello F, Troiani T, Bianco R et al (2006) Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol 17(Suppl 7):vii109–vii114

    Article  PubMed  Google Scholar 

  41. Pastorelli D, Cartei G, Zustovich F et al (2006) Gemcitabine and liposomal doxorubicin in biliary and hepatic carcinoma (HCC) chemotherapy: preliminary results and review of the literature. Ann Oncol 17(Suppl 5): v153–v157

    Article  PubMed  Google Scholar 

  42. Thomas MB, Morris JS, Chadha R et al (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843–850

    Article  CAS  PubMed  Google Scholar 

  43. Sun W, Haller DG, Mykulowycz K et al (2007) Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): a phase II study. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I, vol 25, No. 18S (June 20 Supplement), Abstract No. 4574

    Google Scholar 

  44. Zhu AX, Blaszkowsky LS, Ryan DP et al (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:1898–1903

    Article  CAS  PubMed  Google Scholar 

  45. Louafi S, Boige V, Ducreux M et al (2007) Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study. Cancer 109:1384–1390

    Article  CAS  PubMed  Google Scholar 

  46. O’Neil BH, Bernard SA, Goldberg RM et al (2008) Phase II study of oxaliplatin, capecitabine, and cetuximab in advanced hepatocellular carcinoma. J Clin Oncol, 2008 Gastrointestinal Cancers Symposium, Abstract No. 228

    Google Scholar 

  47. Abou-Alfa GK, Johnson P, Knox J et al (2008) Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC). J Clin Oncol, 2008 ASCO Annual Meeting, vol 26:(May 20 Suppl), Abstract No. 4603

    Google Scholar 

  48. Hsu C, Yang T, Hsu C et al (2008) Phase II study of bevacizumab (A) plus capecitabine (X) in patients (pts) with advanced/metastatic hepatocellular carcinoma (HCC): final report. J Clin Oncol, 2008 Gastrointestinal Cancers Symposium, Abstract No. 128

    Google Scholar 

  49. Mellor HR, Callaghan R (2008) Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81:275–300

    Article  CAS  PubMed  Google Scholar 

  50. Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592–603

    Article  CAS  PubMed  Google Scholar 

  51. Suzuki C, Jacobsson H, Hatschek T et al (2008) Radiologic measurements of tumor response to treatment: practical approaches and limitations. Radiographics 28:329–344

    Article  PubMed  Google Scholar 

  52. Kharuzhyk S, Fabel M, von Tengg-Kobligk H et al (2008) Image-based evaluation of tumor response to treatment: where is radiology today? Exp Oncol 30:181–189

    CAS  PubMed  Google Scholar 

  53. Therasse P, Eisenhauer EA, Verweij J (2006) RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 42:1031–1039

    Article  CAS  PubMed  Google Scholar 

  54. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.[see comment]. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  55. Barros Costa RL (2009) Targeted therapy: comprehensive review. Am J Hosp Palliat Care 26:137–146

    Article  PubMed  Google Scholar 

  56. Gervais DA, Kalva S, Thabet A (2009) Percutaneous image-guided therapy of intra-abdominal malignancy: imaging evaluation of treatment response. Abdom Imaging 34:593–609

    Google Scholar 

  57. Chen K, Li ZB, Wang H et al (2008) Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 35:2235–2244

    Article  CAS  PubMed  Google Scholar 

  58. Jiang HJ, Zhang ZR, Shen BZ et al (2008) Functional CT for assessment of early vascular physiology in liver tumors. Hepatobiliary Pancreat Dis Int 7:497–502

    PubMed  Google Scholar 

  59. Juanyin J, Tracy K, Zhang L et al (2009) Noninvasive imaging of the functional effects of anti-VEGF therapy on tumor cell extravasation and regional blood volume in an experimental brain metastasis model. Clin Exp Metastasis, 2009

    Google Scholar 

  60. Frangioni JV (2008) New technologies for human cancer imaging. J Clin Oncol 26:4012–4021

    Article  PubMed  Google Scholar 

  61. Stadler WM (2007) The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents. Mol Cancer Ther 6:1180–1185

    Article  CAS  PubMed  Google Scholar 

  62. Karrison TG, Maitland ML, Stadler WM et al (2007) Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer. J Natl Cancer Inst 99:1455–1461

    Article  CAS  PubMed  Google Scholar 

  63. Rubinstein L, Crowley J, Ivy P et al (2009) Randomized phase II designs. Clin Cancer Res 15:1883–1890

    Article  CAS  PubMed  Google Scholar 

  64. Shen Y, Hsu C, Hsu C et al (2008) Phase II study of sorafenib plus tegafur/uracil (UFT) in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol, 2008 ASCO Annual Meeting, vol 26:(May 20 Suppl), Abstract No. 15664

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

    Ahmed O. Kaseb

  2. Division of Hematology/Oncology, Department of Medicine, Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA

    Melanie B. Thomas MD, MS

Authors
  1. Ahmed O. Kaseb
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Melanie B. Thomas MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Ambulatory Care Building, 2nd Floor, Department of Surgery, University of Louisville, S. Jackson Street 550, Louisville, 40202, Kentucky, USA

    Kelly M. McMasters

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Kaseb, A.O., Thomas, M.B. (2011). The Future: Combination Systemic Therapy for Hepatocellular Carcinoma. In: McMasters, K. (eds) Hepatocellular Carcinoma:. Springer, New York, NY. https://doi.org/10.1007/978-1-60327-522-4_23

Download citation

  • DOI: https://doi.org/10.1007/978-1-60327-522-4_23

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60327-521-7

  • Online ISBN: 978-1-60327-522-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation